A medical marijuana certification is a state-recognized determination by a licensed physician that a patient has a qualifying medical condition and may benefit from cannabis as part of their care. The certification is what enters the patient into the state registry (in Florida and Georgia) or generates the dispensary prescription (in Texas).

No. Because cannabis remains a Schedule I substance under federal law, state medical-cannabis programs are not covered by health insurance. Patients pay out of pocket for both the physician evaluation and dispensary purchases. Miracle Leaf accepts cash, credit, and debit at all locations.

The typical first visit lasts 20–30 minutes and includes a record review, clinical assessment, and discussion of qualifying conditions, expected benefits, and risks. Renewal visits are shorter. Plan for additional time if you have not received your records before the visit.

Telehealth eligibility varies by state and visit type. Florida permits telehealth for renewals and (under recent rule changes) initial visits in many circumstances. Georgia and Texas have stricter in-person requirements for initial evaluations. Confirm telehealth availability with your scheduling staff before booking.

Miracle Leaf operates a no-card-no-fee policy at most locations: if the physician determines you do not meet the state qualifying-condition criteria, you do not pay the certification fee. Confirm fee terms with your specific clinic before the visit.

A typical initial evaluation is $199. Renewal evaluations are $149. Fees vary slightly by location and any active promotions. Confirm pricing with the specific clinic when you schedule.

Cash, credit, debit, and HSA/FSA cards are accepted at most Miracle Leaf locations. Insurance is not accepted (cannabis remains federally Schedule I).

Discount eligibility varies by location. Many clinics offer veteran and returning-patient discounts. Ask your local clinic when you schedule.

No. Possession of 20 grams or less is a misdemeanor (up to one year in jail, $1,000 fine). Larger amounts scale to felony charges. Amendment 3 of 2024 received 56% support but failed Florida's 60% constitutional supermajority. Smart and Safe Florida's 2026 ballot effort did not certify: state officials validated only 793,000 of the ~1.4 million signatures submitted (880,000 required).

Patients certified by a qualifying physician for one of ten enumerated conditions under §381.986(2): cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, or terminal illness. Plus a comparable-class clause allowing other conditions of the same kind. Chronic nonmalignant pain caused by a qualifying condition also qualifies.

Up to 2.5 ounces of smokable cannabis per 35-day supply window. Non-smokable forms are dispensed up to a 70-day supply. Edibles are capped at 200 mg THC per product and 10 mg THC per serving. Patients must purchase from licensed Medical Marijuana Treatment Centers (MMTCs).

No. Home cultivation is prohibited under §381.986. All medical cannabis must be purchased from licensed Medical Marijuana Treatment Centers (MMTCs).

No. Possession of less than 1 oz is a misdemeanor under O.C.G.A. §16-13-2 with up to 1 year in jail and a $1,000 fine. Possession of more than 1 oz is a felony with 1 to 10 years and a $5,000 fine. Atlanta, Savannah, and Athens-Clarke County operate municipal civil-fine ordinances, but those do not override state law.

Per O.C.G.A. §16-12-201, qualifying conditions include cancer (end-stage or treatment-induced symptoms), ALS, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's, sickle-cell, Tourette syndrome, autism, epidermolysis bullosa, Alzheimer's, AIDS, peripheral neuropathy, hospice or terminal diagnosis, intractable pain, and PTSD. Most conditions require severe or end-stage status.

Registered patients may possess up to 20 fluid ounces of low-THC oil under their state Low-THC Oil Patient Registry ID card. THC content is capped at 5% by weight. Approved product forms are oils, tinctures, transdermal patches, lotions, and capsules. Smokable flower and edibles are prohibited.

No. Home cultivation is prohibited under Georgia law. All low-THC oil must be purchased from a state-licensed dispensary. The first two dispensaries (Trulieve Georgia in Marietta and Botanical Sciences in Macon) opened on April 28, 2023.

No. Recreational cannabis is illegal statewide. Possession of under 2 oz is a Class B misdemeanor with up to 180 days in jail and a $2,000 fine. Larger amounts scale to felony, with substantial quantities triggering 1st-degree felony penalties of up to life under TX Health & Safety Code §§481.121 and 481.122. Austin, Houston, Dallas, and San Antonio operate municipal cite-and-release programs.

Texas Health & Safety Code Chapter 487, as expanded by HB 46 of 2025, lists qualifying conditions: epilepsy and seizure disorders, all cancers, autism spectrum disorder, multiple sclerosis, ALS, spasticity, incurable neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's), PTSD, chronic pain, Crohn's disease, and traumatic brain injury.

TCUP authorizes physician-prescribed low-THC cannabis capped at 1% THC by weight (raised from 0.5% by HB 1535 in 2021). Approved forms are oils, tinctures, capsules, lozenges, patches, lotions, and vaporization (the latter three authorized by HB 46 in 2025). Smokable flower is not permitted. Patients must purchase from one of three licensed dispensaries.

No. Home cultivation is prohibited under TCUP. All medical cannabis must be purchased from a state-licensed dispensary (currently Compassionate Cultivation, Surterra Texas, and Goodblend). Patients pay out of pocket; Texas insurance does not cover TCUP products.

The 2017 NASEM report classified the evidence as conclusive or substantial (its highest tier) that cannabis or cannabinoids are effective for chronic pain in adults. Effect sizes in clinical trials are modest, comparable to other adjunct analgesics, and benefits are most consistent for neuropathic pain.

The 2017 NASEM report concluded there is limited evidence that nabilone (a synthetic cannabinoid) is effective for improving PTSD symptoms. Specifically sleep outcomes. Broader symptom relief from plant cannabis remains an active area of research without conclusive evidence to date.

No. Cannabis itself is not FDA-approved as a cancer treatment. Two synthetic cannabinoids are FDA-approved as antiemetics for chemotherapy-induced nausea and vomiting in patients who have failed standard therapy: dronabinol (Marinol) and nabilone (Cesamet). Plant cannabis is not FDA-approved for any oncology indication.

The evidence is mixed and dose-dependent. The 2017 NASEM report classifies cannabis evidence for anxiety as limited. Low-dose CBD has shown anxiolytic effects in small trials (notably in social-anxiety provocation studies), but higher-dose THC can paradoxically worsen anxiety and trigger panic. The biphasic dose-response means more cannabis is not better.

Cannabidiol (CBD), in the form of the pharmaceutical Epidiolex, is FDA-approved for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older. Plant cannabis is not FDA-approved for epilepsy.